Soligenix Inc. Reports Q2 2025 Results with Progress in Rare Disease Treatments

Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare disease treatments, has shared its Q2 2025 financial results and recent achievements, underscoring significant progress in its late-stage pipeline. The company is on track to release top-line Phase 2a results for SGX302, targeting mild-to-moderate psoriasis, by the end of the year. Additionally, updates from an investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL) are expected, alongside active enrollment in a confirmatory Phase 3 trial for the same condition, with results anticipated in 2026.

Further bolstering its portfolio, Soligenix completed a Phase 2a proof-of-concept study for SGX945 in Behçet’s Disease, meeting its primary objective of demonstrating biological efficacy. The company has also successfully transferred the manufacturing of synthetic hypericin to the U.S. under its partnership with Sterling Pharma Solutions. These developments highlight Soligenix's commitment to addressing unmet medical needs in rare diseases.

Financially, the company reported a Q2 net loss of $2.7 million, or ($0.82) per share, an increase from $1.6 million in the previous period. This was attributed to rising R&D expenses, which reached $1.7 million due to higher trial and manufacturing costs. Despite these challenges, Soligenix maintains a cash position of $5.1 million as of June 30, 2025, supplemented by an additional $1.4 million raised on July 1, ensuring funding for operations into Q1 2026.

For more detailed information on Soligenix's Q2 2025 results and its pipeline progress, visit https://ibn.fm/SsFsy.